🏛️ Verified NIH Record • Updated 2026-08-27
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer (NCT04662580)
A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Janssen Research & Development, LLC
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate cancer (mPC).
Who can join: Review the eligibility criteria below.
Location: UC San Diego Moores Cancer Center — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (12 Sites)
- UC San Diego Moores Cancer Center — La Jolla, California
- University of California, Los Angeles School of Medicine — Los Angeles, California
- UCSF Medical Center at Mission Bay — San Francisco, California
- Winship Cancer Institute of Emory University — Atlanta, Georgia
- Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Washington University St. Louis School Medicine Siteman Cancer Center — St Louis, Missouri
- GU Research Network — Omaha, Nebraska
- Weill Cornell Medical College — New York, New York
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Carolina Urologic Research Center — Myrtle Beach, South Carolina
- University of Washington — Seattle, Washington
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Prostate Cancer
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC — Boston, Massachusetts
- PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer — Boston, Massachusetts
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer — Detroit, Michigan
- Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer — Basking Ridge, New Jersey
- Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers — New York, New York
- Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC — Tucson, Arizona
Explore by condition: All Metastatic Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.